Clinical trial NCT04380922: Prevalence of Periodontal Diseases in IBD
Official title: Prevalence of Periodontal Diseases in Inflammatory Bowel Diseases : a Pilot-study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inflammatory Bowel Diseases
Periodontal Diseases
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2020-05-08
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients consulting for the management of Crohn's disease or Ulcerative colitis

Brief summary: Periodontal diseases are highly prevalent inflammatory diseases. It is now well known that they are correlated with numerous systemic diseases as : diabetes, chronic obstructive pulmonary disease, metabolic syndrome or rheumatoid arthritis. Recently, periodontal diseases have been correlated with inflammatory bowel diseases (IBD). IBD include two types, Crohn's disease and Ulcerative Colitis. It could be a significant risk factor for the pathogenesis of periodontal disease. These diseases present common features : a high prevalence worldwide, multifactorial pathogenies with common mechanisms. To date, no study has linked activity of IBD and periodontal diseases. The authors hypotheses that the prevalence of periodontal diseases could be increased in patient presenting an active IBD

Detailed description: The present study explores the prevalence of periodontal diseases regarding to the activity status of IBD (active versus non-active).

Diseases activity will be assessed by HBI (Crohn's disease) or partial Mayo score (Ulcerative Colitis) associated with fecal calprotectin and/or CRP and/or inflammatory/ulcerative lesions.

Periodontal diseases (periodontitis and gingivitis) will be diagnosed according to the international classification of periodontal diseases (Chicago 2017) and based on the decision-making algorithms by Tonetti and Sanz. A periodontal screening, socio-demographic data and clinical data will be collected. Then, oral mucosa dermatological manifestations relative to IBD, treatment need (ICDAS) and quality of life related to oral health (GOHAI) will be evaluated. These data will be collected by a periodontist.

The principal hypothesis of this study is that the prevalence of periodontal diseases could be increased in patient presenting an active IBD.

The primary objective is to evaluate if patients presenting active IBD present more stage III and IV periodontal diseases than non-active IBD ones.

The second objectives are :

* to compare periodontal diseases, gingivitis and oral mucosa dermatological manifestations rates according to the diseases activity, the IBD type and the treatment used to treat IBD,
* to compare oral treatment need according to the activity and the type of IBD,
* to compare quality of life related to oral health according to the activity and the type of IBD

Eligibility criteria: Inclusion Criteria:

Patients

* consulting Gastroenterology departments in the university hospital of Reims or Amiens-Picardie for the management of Crohn's disease or Ulcerative colitis
* signed informed consent form
* affiliated to the French Social Security system

Exclusion Criteria:

Patients presenting:

* a medical history likely to compromise protocol (psychiatric disorders, other inflammatory diseases, antibiotics, NSAIDs within the last 3 months)
* Diabetes
* Inflammatory rheumatism
* Cancer or radiotherapy up to5 years before inclusion
* X-ray therapy in the area of interest
* Pregnancy or Breastfeeding
* Eating disorders
* Patients under legal protection, trusteeship or guardianship

Primary outcomes:
measure: Prevalence of Periodontal Disease
timeFrame: Day 0
Secondary outcomes:
measure: Gingivitis
timeFrame: Day 0
measure: Oral mucosa dermatological manifestations secondary to IBD
timeFrame: Day 0
measure: Oral Health Quality of Life
timeFrame: Day 0
measure: Oral treatment need
timeFrame: Day 0
Other outcomes:
Locations:
city: Reims
country: France
facility: Chu Reims
Study officials:
References: